To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients

NCT03423225 | Completed Phase 4

• 1 other identifier: Assign
• Study Type: interventional
• Target: 31
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study's objective is to evaluate the incidence rate of acute rejection reactions after 24 weeks treatment with ADVAGRAF® following 3 months treatment with tacrolimus in new liver transplant recipients. Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.

Conditions

Liver Transplantation

Keywords

ADVAGRAF®; Liver Transplantation; tacrolimus

Outcome Measures

Primary Outcomes (1)

• Incidence rate of acute rejection reaction confirmed by biopsy within 24 weeks after conversion

  Incidence rate of acute rejection reaction (%) = The number of subjects with at least one acute rejection reaction / Total number of subjects included in the analysis group \* 100 number of subjects in the relevant analysis set \* 100

  within 24 weeks

Secondary Outcomes (4)

• Severity of acute rejection reaction confirmed by biopsy within 24 weeks after conversion

  within 24 weeks

• Survival rates of subjects after conversion

  at week 24

• Survival rate of transplanted organs after conversion

  at week 24

• Blood concentration of tacrolimus

  at week -4, week 0, week 2, week 4, week 8, week 16 and week 24

Study Arms (1)

ADVAGRAF®

EXPERIMENTAL

One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.

Drug: ADVAGRAF®

Interventions

ADVAGRAF® DRUG

Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast). * Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment. * Duration of treatment The investigational product will be administered for 24 weeks.

Also known as: tacrolimus

ADVAGRAF®

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• When the Subjects agree informed consent form, Subject should be More than 20 years of age
• Those who was transplanated liver at a minimum of 10 weeks or Maximum of 14 weeks before the baseline
• Average of tacrorimus minimum blood concenration level is 3-10 ng/mL from transplanted date to baseline.
• Female subjects who have child bearing potential must have a negative at urine or serum pregnancy test prior to enrollment and must agree to practice effective contraceptive measures during the study.(The oral contraceptive pill is not allowed to take a female subject)
• Subjects who are clinically stable judged by investigator.
• Subjects capable of understanding the purpose and risks of the study, having been fully informed and has given written informed consent to participate in the study

You may not qualify if:

• Subjects previously received an organ transplantation excluding liver transplantation. Or Subjects received an auxiliary graft or bioartificial liver(cell system).
• Recently there was acute rejection from the day of liver transplantation to baseline
• If the onset of a new malignant cancer after liver transplantation is diagnosed, well treated basal cell carcinoma or squamous cell carcinoma is classified as an exception
• When it is known that there is a hypersensitivity reaction to the ingredients of tacrolimus or the test drug
• In the opinion of the investigator, there is an unstable medical condition that can affect the purpose of the clinical trial
• In the event of material abuse, mental disorder or anything that can not smoothly communicate with the inverstigator in the opinion of the investigator
• Currently, if subjects are participating in other clinical trials or if subjects receive another drug for clinical trials within 28 days before baseline
• If subjects have received a prohibited combination therapy currently or within 28 days before the baseline
• Pregnant or lactating women
• If known for HIV-positive
• When there is a high possibility that subject will not be able to obey the visit schedule planned in protocol
• Those who have clinically significant renal dysfunction judged by the investigator or at baseline serum creatinine level exceeds 1.6 mg / dL or GFR (MDRD) is less than 30 mL / min
• Those who have clinically significant liver function disorder judged by the investigator or at the baseline, the values of SGPT / ALT and / or SGOT / AST and / or bilirubin are more than three times the upper limit of the laboratory normal range When raised

Sponsors & Collaborators

• Kim, Seoung-Hoon: lead
• Astellas Pharma Korea, Inc.: collaborator
• Linical Korea: collaborator

MeSH Terms

Interventions

Tacrolimus

Intervention Hierarchy (Ancestors)

Macrolides; Lactones; Organic Chemicals

Study Officials

• Seoung-Hoon Kim, doctoral

  National Cancer Center, Republic of Korea

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of Organ transplantation department

Study Record Dates

• First Submitted: January 22, 2018
• First Posted: February 6, 2018
• Study Start: March 22, 2016
• Primary Completion: July 18, 2017
• Study Completion: December 14, 2017
• Last Updated: February 6, 2018

Record last verified: 2018-02

Data Sharing

• IPD Sharing: Will not share